Celldex Therapeutics
CLDX
193 hedge funds and large institutions have $2.43B invested in Celldex Therapeutics in 2015 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 18 closing their positions.
172% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 18
64% more capital invested
Capital invested by funds: $1.48B → $2.43B (+$953M)
18% more funds holding
Funds holding: 163 → 193 (+30)
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
16% less call options, than puts
Call options by funds: $51.6M | Put options by funds: $61.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$113M |
| 2 |
Millennium Management
New York
|
+$47.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$21.4M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$34.9M |
| 2 |
Bank of New York Mellon
New York
|
-$23.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$21.4M |
| 4 |
CCI
Columbus Circle Investors
|
-$16.2M |
| 5 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$12.5M |
CLDX Hedge Fund Activity: Q1 2015 in Review
193 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2015, worth a combined $2.43B — up 64% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CLDX positions and 18 closed out — a net gain of 31 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was First Trust Advisors, opening a new position worth an estimated $113M. The largest seller was OrbiMed, cutting an estimated $34.9M.
- 193 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2015, up from 163 in Q4 2014.
- Funds reported $2.43B of Celldex Therapeutics stock for Q1 2015, up 64% quarter-over-quarter.
- 49 funds opened new Celldex Therapeutics positions in Q1 2015 and 18 closed out, a net change of +31 holders.
- The largest Celldex Therapeutics buyer in Q1 2015 was First Trust Advisors, an estimated $113M added.
- The largest Celldex Therapeutics seller in Q1 2015 was OrbiMed, an estimated $34.9M sold.
Based on aggregated 13F filings for Q1 2015.